Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Pension (2017 - 2025)

Historic Pension for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $3.0 million.

  • Innate Pharma's Pension rose 1345.5% to $3.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $3.0 million, marking a year-over-year increase of 1345.5%. This contributed to the annual value of $3.0 million for FY2024, which is 1190.36% up from last year.
  • As of Q2 2025, Innate Pharma's Pension stood at $3.0 million, which was up 1345.5% from $2.9 million recorded in Q4 2024.
  • Over the past 5 years, Innate Pharma's Pension peaked at $4.7 million during Q2 2021, and registered a low of $2.6 million during Q4 2022.
  • For the 5-year period, Innate Pharma's Pension averaged around $3.1 million, with its median value being $2.9 million (2022).
  • As far as peak fluctuations go, Innate Pharma's Pension crashed by 9988.76% in 2021, and later skyrocketed by 1345.5% in 2025.
  • Innate Pharma's Pension (Quarter) stood at $3.4 million in 2021, then decreased by 23.56% to $2.6 million in 2022, then increased by 0.95% to $2.6 million in 2023, then rose by 11.08% to $2.9 million in 2024, then increased by 3.45% to $3.0 million in 2025.
  • Its Pension stands at $3.0 million for Q2 2025, versus $2.9 million for Q4 2024 and $2.7 million for Q2 2024.